Akebia - Bathi saben saham sajrone 12 wulan pungkasan AKBA

Simbol resmi perusahaan Akebia Therapeutics Inc (AKBA)

Akebia Therapeutics (AKBA) has transitioned to commercial expansion following the approval of its anemia drug. This trailing twelve-month EPS chart on GURU.Markets captures this growth, with the indicator reaching -118.60. Sales diversification across Asia, Europe, and the US minimizes patent risks, while a focus on chronic kidney disease therapies ensures stable supplies to clinics.

AKBA: Bathi resik saben saham (EPS TTM) Akebia 11.02.2024 - 19.11.2026

Akebia Corp - rincian analitis lan metrik utama (AKBA)

Analisis wiwitan perusahaan:AKBA - Akebia Therapeutics, Inc.
Barang utama Akebia

The implementation of energy-saving systems and emission filtration in Akebia Therapeutics (AKBA) laboratories directly impacts operating expenses, affecting the bottom line. The trend in trailing twelve-month (TTM) net income per share measures the efficiency of business scaling amid tight monetary policy, allowing the EPS YoY TTM growth rate chart to diagnose hidden risks of capital stagnation.